Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy.

Williford JM, Ishihara J, Ishihara A, Mansurov A, Hosseinchi P, Marchell TM, Potin L, Swartz MA, Hubbell JA.

Sci Adv. 2019 Dec 11;5(12):eaay1357. doi: 10.1126/sciadv.aay1357. eCollection 2019 Dec.

2.

Targeted antibody and cytokine cancer immunotherapies through collagen affinity.

Ishihara J, Ishihara A, Sasaki K, Lee SS, Williford JM, Yasui M, Abe H, Potin L, Hosseinchi P, Fukunaga K, Raczy MM, Gray LT, Mansurov A, Katsumata K, Fukayama M, Kron SJ, Swartz MA, Hubbell JA.

Sci Transl Med. 2019 Apr 10;11(487). pii: eaau3259. doi: 10.1126/scitranslmed.aau3259.

3.

Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.

Ishihara J, Ishihara A, Potin L, Hosseinchi P, Fukunaga K, Damo M, Gajewski TF, Swartz MA, Hubbell JA.

Mol Cancer Ther. 2018 Nov;17(11):2399-2411. doi: 10.1158/1535-7163.MCT-18-0091. Epub 2018 Aug 10.

4.

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.

Ishihara J, Fukunaga K, Ishihara A, Larsson HM, Potin L, Hosseinchi P, Galliverti G, Swartz MA, Hubbell JA.

Sci Transl Med. 2017 Nov 8;9(415). pii: eaan0401. doi: 10.1126/scitranslmed.aan0401.

PMID:
29118259

Supplemental Content

Loading ...
Support Center